Orexo AB Company Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally.

Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia.

The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.

In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder.

The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology.

Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Orexo AB (publ)

Country	Sweden
Founded	1994
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	110
CEO	Nikolaj Sorensen

Contact Details

Address: Rapsgatan 7E Uppsala, Uppsala County Uppsala County Sweden
Phone	46 1 87 80 88 00
Website	orexo.com

Stock Details

Ticker Symbol	ORX
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0000736415
SIC Code	2834

Key Executives

Name	Position
Nikolaj Sorensen	President and Chief Executive Officer
Fredrik Jarrsten	Executive Vice President and Chief Financial Officer
Cecilia Coupland	Senior Vice President and Head of Operations
Lena Wange	Investor Relations and Communications Director
Robert Ronn	Senior Vice President and Head of Research & Development
Dr. Edward Kim M.B.A., M.D.	Chief Medical Officer
Robert A. Deluca BS Pharm	President of Orexo US Inc
Jesper Lind	Advisor